VP 16-213 and cytosine-arabinoside combination chemotherapy for refractory acute lymphoblastic leukemia in adults

E. Morra, M. Lazzarino, E. P. Alessandrino, D. Inverardi, A. Canevari, C. Bernasconi

Research output: Contribution to journalArticlepeer-review

Abstract

Fifteen adult patients with refractory or relapsing acute lymphoblastic leukemia (ALL) received a 5-day remission induction regimen consisting of VP 16-213 (60 mg/m2 every 12 hr) and cytosine-arabinoside (100 mg/m2 every 12 hr) up to a maximum of three courses. The overall response rate was 60% ( 9 15), four patients (27%) achieving CR and five (33%) attaining PR. Responders were maintained with monthly courses of the same combination until progressive disease developed. The median duration of response was 4.5 months (2-12+ months). The regimen was relatively well tolerated. The major toxicity was hematologic. Non-hematologic toxicities included mild nausea and vomiting ( 11 15) and total alopecia ( 15 15). The results obtained with this combination are encouraging, in view of the poor prognosis associated with refractory or relapsing ALL in adults.

Original languageEnglish
Pages (from-to)1471-1475
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Volume20
Issue number12
DOIs
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'VP 16-213 and cytosine-arabinoside combination chemotherapy for refractory acute lymphoblastic leukemia in adults'. Together they form a unique fingerprint.

Cite this